Odyssey Therapeutics, Inc. Common Stock (NASDAQ:ODTX) — Market Cap & Net Worth
Market Cap & Net Worth: Odyssey Therapeutics, Inc. Common Stock (ODTX)
Odyssey Therapeutics, Inc. Common Stock (NASDAQ:ODTX) has a market capitalization of $870.82 Million ($870.82 Million) as of October 12, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9496 globally and #2619 in its home market, demonstrating a -6.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Odyssey Therapeutics, Inc. Common Stock's stock price $19.00 by its total outstanding shares 48058527 (48.06 Million).
Odyssey Therapeutics, Inc. Common Stock Market Cap History: 2026 to 2026
Odyssey Therapeutics, Inc. Common Stock's market capitalization history from 2026 to 2026. Data shows growth from $913.11 Million to $913.11 Million (0.00% CAGR). Check ODTX stock price and chart for real-time trading data and today's change.
Odyssey Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Odyssey Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Odyssey Therapeutics, Inc. Common Stock for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ODTX by Market Capitalization
Companies near Odyssey Therapeutics, Inc. Common Stock in the global market cap rankings as of October 12, 2026. See net asset quality index of Odyssey Therapeutics, Inc. Common Stock to understand what proportion of total assets are financed by equity.
Key companies related to Odyssey Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Odyssey Therapeutics, Inc. Common Stock Historical Marketcap From 2026 to 2026
Between 2026 and today, Odyssey Therapeutics, Inc. Common Stock's market cap moved from $913.11 Million to $ 913.11 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $913.11 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 12th, 2026 the market cap of Odyssey Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $870.82 Million USD |
| MoneyControl | $870.82 Million USD |
| MarketWatch | $870.82 Million USD |
| marketcap.company | $870.82 Million USD |
| Reuters | $870.82 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Odyssey Therapeutics, Inc. Common Stock
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated … Read more